By WSJ Staff
Shares of Kenvue fell 13% Thursday to $14.11, its lowest finish since the consumer healthcare firm spun off from Johnson & Johnson in 2023. The decline was the sharpest on record for Kenvue, according to Dow Jones Market Data. The fall surpassed the day last month that President Trump warned that the active ingredient in Kenvue's Tylenol is a potential cause of autism. Kenvue has said that Tylenol is safe and that the science shows no clear link between it and autism.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
October 16, 2025 16:43 ET (20:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.